MAD2L2 and cancer: Multiple studies in cancers have shown that Rev7 inhibits DNA end-resection and favors NHEJ over HR (Gupta et al., 2018; Ghezraoui et al., 2018; Dev et al., 2018; Gao et al., 2018; Liang et al., 2020).